Switch theme
Sign up to access all valuation multiples
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.
2020
1K+
LTM Revenue $332M
LTM EBITDA $23.4M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GeneDx has a last 12-month revenue (LTM) of $332M and a last 12-month EBITDA of $23.4M.
In the most recent fiscal year, GeneDx achieved revenue of $305M and an EBITDA of -$1.3M.
GeneDx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GeneDx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $332M | XXX | $305M | XXX | XXX | XXX |
| Gross Profit | $217M | XXX | $194M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $23.4M | XXX | -$1.3M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 0% | XXX | XXX | XXX |
| EBIT | $19.4M | XXX | -$23.2M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | $16.9M | XXX | -$52.3M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GeneDx's stock price is $71.
GeneDx has current market cap of $2.0B, and EV of $2.0B.
See GeneDx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.0B | XXX | XXX | XXX | XXX | $0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GeneDx has market cap of $2.0B and EV of $2.0B.
GeneDx's trades at 6.5x EV/Revenue multiple, and -1577.4x EV/EBITDA.
Equity research analysts estimate GeneDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GeneDx has a P/E ratio of 120.5x.
See valuation multiples for GeneDx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBITDA | 84.9x | XXX | -1577.4x | XXX | XXX | XXX |
| EV/EBIT | 102.2x | XXX | -85.6x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 120.5x | XXX | -38.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -58.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGeneDx's last 12 month revenue growth is 19%
GeneDx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
GeneDx's rule of 40 is -48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GeneDx's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GeneDx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Growth | 134% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -48% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GeneDx acquired XXX companies to date.
Last acquisition by GeneDx was XXXXXXXX, XXXXX XXXXX XXXXXX . GeneDx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GeneDx founded? | GeneDx was founded in 2020. |
| Where is GeneDx headquartered? | GeneDx is headquartered in United States of America. |
| How many employees does GeneDx have? | As of today, GeneDx has 1K+ employees. |
| Who is the CEO of GeneDx? | GeneDx's CEO is Ms. Katherine A. Stueland. |
| Is GeneDx publicy listed? | Yes, GeneDx is a public company listed on NAS. |
| What is the stock symbol of GeneDx? | GeneDx trades under WGS ticker. |
| When did GeneDx go public? | GeneDx went public in 2021. |
| Who are competitors of GeneDx? | Similar companies to GeneDx include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of GeneDx? | GeneDx's current market cap is $2.0B |
| What is the current revenue of GeneDx? | GeneDx's last 12 months revenue is $332M. |
| What is the current revenue growth of GeneDx? | GeneDx revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of GeneDx? | Current revenue multiple of GeneDx is 6.0x. |
| Is GeneDx profitable? | Yes, GeneDx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GeneDx? | GeneDx's last 12 months EBITDA is $23.4M. |
| What is GeneDx's EBITDA margin? | GeneDx's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of GeneDx? | Current EBITDA multiple of GeneDx is 84.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
